COMP <GO>
COGT vs UNH // GROSS PROFIT MARGIN
Cogent Biosciences Inc. (NASDAQ) VS. UnitedHealth Group Incorporated (NYSE) • 15-METRIC TALLY: COGT 3
— UNH 11
▲ GROSS PROFIT MARGIN LEADER: UNH
LAST: $31.02 (-2.94%) • MKT CAP: $5.55B
gross-margins
41.00%
LAST: $406.97 (-0.96%) • MKT CAP: $364.66B
gross-margins
88.57%
15-METRIC INSTITUTIONAL SIDE-BY-SIDE SCORECARD (COGT VS. UNH)
EMERALD CELL = QUANTITATIVE EDGE
| INSTITUTIONAL METRIC | COGT | UNH | SPREAD (A - B) | ADVANTAGE | DEDICATED URL |
|---|---|---|---|---|---|
| Gross Profit Margin ACTIVE | 41.00% | 88.57% | -47.57 | UNH | /gross-margins <GO> |
| Return on Invested Capital (ROIC) | -35.00% | 11.47% | -46.47 | UNH | /roic <GO> |
| EV/EBITDA & P/E Valuation | — | 16.4x | — | TIE | /valuation <GO> |
| Free Cash Flow Yield | -4.80% | 6.48% | -11.28 | UNH | /fcf-yield <GO> |
| Operating Margin | -21.50% | 4.82% | -26.32 | UNH | /operating-margins <GO> |
| Net Profit Margin | -21.20% | 3.14% | -24.34 | UNH | /net-margins <GO> |
| Revenue Growth (YoY) | 22.00% | 6.46% | +15.54 | COGT | /revenue-growth <GO> |
| Dividend Yield & FCF Payout Safety | 0.00% | 2.28% | -2.28 | UNH | /dividend-safety <GO> |
| Altman Z-Score & Debt/Equity | 10.84 | 3.12 | +7.72 | COGT | /balance-sheet <GO> |
| Piotroski F-Score Quality | 5/9 | 7/9 | -2.00 | UNH | /piotroski-score <GO> |
| Options Implied Move & Put/Call Skew | 7.10% | 6.74% | +0.36 | UNH | /options-implied-move <GO> |
| RSI-14 & 200D SMA Momentum | 47.4 | 56.0 | -8.65 | UNH | /rsi-technicals <GO> |
| 10Y Yield & FRED Macro Beta | 1.05 | 0.33 | +0.72 | COGT | /macro-sensitivity <GO> |
| Forward P/E Multiple | 22.0x | 17.1x | +4.91 | UNH | /forward-pe <GO> |
| Enterprise Scale & Market Cap | $5.55B | $364.66B | -$359.11B | UNH | /market-cap <GO> |
5-YEAR HISTORICAL XBRL REVENUE & MARGIN TRAJECTORY SEC FORM 10-K FY
| FISCAL YEAR | COGT REV | UNH REV | COGT GROSS % | UNH GROSS % | COGT FCF | UNH FCF |
|---|---|---|---|---|---|---|
| FY 2025 | $0 | $447.57B | — | 88.7% | -$266.0M | $16.07B |
| FY 2024 | $0 | $400.28B | — | 88.3% | -$208.4M | $20.70B |
| FY 2023 | $0 | $371.62B | — | 89.6% | -$153.6M | $25.68B |
| FY 2022 | — | $324.16B | — | 89.6% | — | $23.40B |
| FY 2021 | — | $287.60B | — | 89.2% | — | $19.89B |
FRED MACRO REGIME CORRELATION COMPARISON PEARSON r
COGT // BETA 1.05
UNH // BETA 0.33